A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. Issue 3 (1st March 2022)
- Record Type:
- Journal Article
- Title:
- A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. Issue 3 (1st March 2022)
- Main Title:
- A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity
- Authors:
- Akin, Sakir
Schriek, Paula
van Nieuwkoop, Cees
Neuman, Rugina I.
Meynaar, Iwan
van Helden, Erik J.
Bouazzaoui, Hassan El
Baak, Remon
Veuger, Marjan
Mairuhu, Ronne A.T.A.
van den Berg, Lettie
van Driel, Vincent
Visser, Loes E.
de Jonge, Evert
Garrelds, Ingrid M.
Duynstee, Johannes F.A.B.
van Rooden, Jan Kees
Ludikhuize, Jeroen
Verdonk, Koen
Caliskan, Kadir
Jansen, Tim
van Schaik, Ron H.N.
Danser, A.H. Jan - Abstract:
- Abstract : Background: The severity of COVID-19 after SARS-CoV-2 infection is unpredictable. Angiotensin-converting enzyme-2 (ACE2) is the receptor responsible for coronavirus binding, while subsequent cell entry relies on priming by the serine protease TMPRSS2 (transmembrane protease, serine 2). Although renin-angiotensin-aldosterone-system (RAAS) blockers have been suggested to upregulate ACE2, their use in COVID-19 patients is now considered well tolerated. The aim of our study was to investigate parameters that determine COVID-19 severity, focusing on RAAS-components and variation in the genes encoding for ACE2 and TMPRSS2. Methods: Adult patients hospitalized due to SARS-CoV-2 infection between May 2020 and October 2020 in the Haga Teaching Hospital were included, and soluble ACE2 (sACE2), renin, aldosterone (in heparin plasma) and polymorphisms in the ACE2 and TMPRSS2 genes (in DNA obtained from EDTA blood) were determined. Measurements and main results: Out of the 188 patients who were included, 60 were defined as severe COVID-19 (ICU and/or death). These patients more often used antidiabetic drugs, were older, had higher renin and sACE2 levels, lower aldosterone levels and a lower aldosterone/renin ratio. In addition, they displayed the TMPRSS2-rs2070788 AA genotype less frequently. No ACE2 polymorphism-related differences were observed. Multivariate regression analysis revealed independent significance for age, sACE2, the aldosterone/renin ratio, and the TMPRSS2Abstract : Background: The severity of COVID-19 after SARS-CoV-2 infection is unpredictable. Angiotensin-converting enzyme-2 (ACE2) is the receptor responsible for coronavirus binding, while subsequent cell entry relies on priming by the serine protease TMPRSS2 (transmembrane protease, serine 2). Although renin-angiotensin-aldosterone-system (RAAS) blockers have been suggested to upregulate ACE2, their use in COVID-19 patients is now considered well tolerated. The aim of our study was to investigate parameters that determine COVID-19 severity, focusing on RAAS-components and variation in the genes encoding for ACE2 and TMPRSS2. Methods: Adult patients hospitalized due to SARS-CoV-2 infection between May 2020 and October 2020 in the Haga Teaching Hospital were included, and soluble ACE2 (sACE2), renin, aldosterone (in heparin plasma) and polymorphisms in the ACE2 and TMPRSS2 genes (in DNA obtained from EDTA blood) were determined. Measurements and main results: Out of the 188 patients who were included, 60 were defined as severe COVID-19 (ICU and/or death). These patients more often used antidiabetic drugs, were older, had higher renin and sACE2 levels, lower aldosterone levels and a lower aldosterone/renin ratio. In addition, they displayed the TMPRSS2-rs2070788 AA genotype less frequently. No ACE2 polymorphism-related differences were observed. Multivariate regression analysis revealed independent significance for age, sACE2, the aldosterone/renin ratio, and the TMPRSS2 rs2070788 non-AA genotype as predictors of COVID-19 severity, together yielding a C-index of 0.79. Findings were independent of the use of RAAS blockers. Conclusion: High sACE2, a low aldosterone/renin ratio and having the TMPRSS2 rs2070788 non-AA genotype are novel independent determinants that may help to predict COVID-19 disease severity. Trial registration: retrospectively registered. … (more)
- Is Part Of:
- Journal of hypertension. Volume 40:Issue 3(2022)
- Journal:
- Journal of hypertension
- Issue:
- Volume 40:Issue 3(2022)
- Issue Display:
- Volume 40, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 3
- Issue Sort Value:
- 2022-0040-0003-0000
- Page Start:
- 606
- Page End:
- 614
- Publication Date:
- 2022-03-01
- Subjects:
- aldosterone -- angiotensin-converting enzyme-2 -- COVID-19 -- renin -- TMPRSS2
Hypertension -- Periodicals
Hypertension -- Periodicals
616.132005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://journals.lww.com/jhypertension/pages/default.aspx ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00004872-000000000-00000 ↗
http://www.jhypertension.com/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/HJH.0000000000003054 ↗
- Languages:
- English
- ISSNs:
- 1473-5598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5004.510000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25380.xml